OPKO Health Dirección
Dirección controles de criterios 3/4
OPKO Health's El consejero delegado es Phil Frost , nombrado en Mar 2007, tiene un mandato de 17.08 años. la remuneración anual total es $2.28M , compuesta por 42.2% salario y 57.8% primas, incluidas acciones y opciones de la empresa. posee directamente 35.03% de las acciones de la empresa, por valor de $293.00M . La antigüedad media del equipo directivo y del consejo de administración es de 9.1 años y 11.1 años respectivamente.
Información clave
Phil Frost
Chief Executive Officer (CEO)
US$2.3m
Compensación total
| Porcentaje del salario del CEO | 42.2% |
| Permanencia del CEO | 17.1yrs |
| Participación del CEO | 35.0% |
| Permanencia media de la dirección | 9.1yrs |
| Promedio de permanencia en la Junta Directiva | 15yrs |
Actualizaciones recientes de la dirección
Recent updates
OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar
Dec 30
Is OPKO Health (NASDAQ:OPK) A Risky Investment?
Oct 03OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up
Jul 24Would OPKO Health (NASDAQ:OPK) Be Better Off With Less Debt?
Jun 07Is OPKO Health (NASDAQ:OPK) Using Too Much Debt?
Jan 04OPKO Health: Assessing If Significant Potential Can Be Realized
Sep 15OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
Sep 05OPKO Health: 14%+ Short Interest Means More Volatility Over The Near Term
Jun 21OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
Apr 29OPKO Health: A Great Long-Term Investment In Health
Apr 05OPKO Health Is Risky But Might Make You Money
Mar 29Analysts Have Just Cut Their OPKO Health, Inc. (NASDAQ:OPK) Revenue Estimates By 14%
Feb 27OPKO Health (NASDAQ:OPK) Has A Pretty Healthy Balance Sheet
Jan 12OPKO Health: Undervalued Opportunity
Dec 23OPKO Health: Bullish Case Still Intact
Dec 15We Think OPKO Health (NASDAQ:OPK) Can Stay On Top Of Its Debt
Sep 27OPKO Health: A Defensive, Long-Term Holding
Sep 19Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$960k | -US$189m |
| Sep 30 2023 | n/a | n/a | -US$208m |
| Jun 30 2023 | n/a | n/a | -US$209m |
| Mar 31 2023 | n/a | n/a | -US$291m |
| Dec 31 2022 | US$972k | US$960k | -US$328m |
| Sep 30 2022 | n/a | n/a | -US$317m |
| Jun 30 2022 | n/a | n/a | -US$202m |
| Mar 31 2022 | n/a | n/a | -US$117m |
| Dec 31 2021 | US$2m | US$960k | -US$30m |
| Sep 30 2021 | n/a | n/a | US$76m |
| Jun 30 2021 | n/a | n/a | US$71m |
| Mar 31 2021 | n/a | n/a | US$121m |
| Dec 31 2020 | US$2m | US$960k | US$31m |
| Sep 30 2020 | n/a | n/a | -US$114m |
| Jun 30 2020 | n/a | n/a | -US$200m |
| Mar 31 2020 | n/a | n/a | -US$293m |
| Dec 31 2019 | US$1m | US$960k | -US$315m |
| Sep 30 2019 | n/a | n/a | -US$279m |
| Jun 30 2019 | n/a | n/a | -US$244m |
| Mar 31 2019 | n/a | n/a | -US$191m |
| Dec 31 2018 | US$2m | US$960k | -US$153m |
| Sep 30 2018 | n/a | n/a | -US$295m |
| Jun 30 2018 | n/a | n/a | -US$303m |
| Mar 31 2018 | n/a | n/a | -US$314m |
| Dec 31 2017 | US$971k | US$960k | -US$305m |
Compensación vs. Mercado: Phil($USD2.28M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD3.27M).
Compensación vs. Ingresos: Philha aumentado mientras la empresa no es rentable.
CEO
Phil Frost (87 yo)
17.1yrs
Permanencia
US$2,277,200
Compensación
Dr. Phillip Frost, also known as Phil, M.D., Ph D., is Director of Non-Invasive Monitoring Systems, Inc. since June 01, 2023. He has been the Chairman, Chief Executive Officer and Director of OPKO Health,...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 17.1yrs | US$2.28m | 35.03% $ 300.3m | |
| Vice Chairman & Chief Technical Officer | 17.2yrs | US$2.19m | 4.75% $ 40.7m | |
| President & Vice Chairman | 1.9yrs | US$2.19m | 2.93% $ 25.1m | |
| Senior VP | 17.1yrs | US$1.81m | 0.026% $ 220.4k | |
| Executive VP of Administration & Director | 16.9yrs | US$1.94m | 0.89% $ 7.6m | |
| Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal | 7.1yrs | sin datos | sin datos | |
| Chief Innovation Officer & Director | 1.9yrs | sin datos | 5.75% $ 49.3m | |
| Chief Executive Officer of OPKO Renal | 11.1yrs | sin datos | sin datos | |
| President of Transition Therapeutics | no data | sin datos | sin datos | |
| President of OPKO Health Iberoamerica | no data | sin datos | sin datos | |
| Chief Executive Officer of EirGen Pharma | 4.4yrs | sin datos | sin datos | |
| Interim CEO | 1.7yrs | sin datos | sin datos |
9.1yrs
Permanencia media
70.5yo
Promedio de edad
Equipo directivo experimentado: OPKEl equipo directivo de la empresa es veterano y experimentado (10.8 años de antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 17.1yrs | US$2.28m | 35.03% $ 300.3m | |
| Vice Chairman & Chief Technical Officer | 17.2yrs | US$2.19m | 4.75% $ 40.7m | |
| President & Vice Chairman | 1.9yrs | US$2.19m | 2.93% $ 25.1m | |
| Executive VP of Administration & Director | 17.2yrs | US$1.94m | 0.89% $ 7.6m | |
| Chief Innovation Officer & Director | 1.9yrs | sin datos | 5.75% $ 49.3m | |
| Independent Director | 3.3yrs | US$69.90k | 0% $ 0 | |
| Lead Independent Director | 16.3yrs | US$134.80k | 0.047% $ 399.8k | |
| Independent Director | 7.2yrs | US$92.40k | 0.015% $ 127.1k | |
| Independent Director | 20.3yrs | US$84.90k | 0.056% $ 484.0k | |
| Independent Director | 3.1yrs | US$92.40k | 0% $ 0 | |
| Independent Director | 15yrs | US$62.40k | 0.0095% $ 81.8k |
15.0yrs
Permanencia media
76yo
Promedio de edad
Junta con experiencia: OPKLos consejos de administración de la empresa son veteranos y experimentados ( 15.3 años de permanencia media en el cargo).